The global myocardial infarction market is anticipated to grow at a CAGR of around 6.6% during the forecast period (2021-2027). Factors contributing to the growth of the myocardial infarction market include rising incidence rate of CVDs (cardiovascular diseases) and intake of high-level sugary food, which significantly boost the prevalence of CADs (coronary artery diseases). According to the American Heart Association estimates, CVD is the leading global cause of death and accounted for approximately 18.6 million deaths in 2019. Further, according to WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. 4 out of 5 CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age. Due to the rising prevalence of cardiovascular disease which is the leading cause of mortality, the demand for early detection technologies and diagnostic methods such as ECG, CT-Scan, Echocardiography is increasing, which further driving the market growth.
Browse the full report description of "Global Myocardial Infarction Market Size, Share & Trends Analysis Report By Type (NSTEMI, STEMI, and Silent Heart Attacks) By Device (Left Ventricular Assist Device, Pacemaker, Catheters, Implantable Cardioverter Defibrillator, and Others) By Diagnosis (ECG, Chest X-Ray, Computed Tomography (CT Scan), Echocardiography, and Others ) By Treatment (Medication, and Surgery) By End-Users (Hospitals and Clinics, Ambulatory Surgical Centers, and Research Institutes) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/myocardial-infarction-market
Apart from this, the major market players are also taking initiatives by adopting various strategies such as mergers and acquisitions to expand their product offering and launching new technologies to fulfil the demands of the market and healthcare sector. For instance, in October 2020, Abbott had launched next-generation heart rhythm management devices, the Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) in India. The devices are used for people with abnormal heart rhythms and heart failure. Both the devices offer patient engagement and remote monitoring through smartphone connectivity and connected applications. Moreover, in Jan 2021, Boston Scientific has announced the acquisition of Preventice Solutions, Inc, which offers a full portfolio of mobile cardiac health solutions and services. The acquisition was under a definitive agreement of $925 million. The acquisition will aid Boston Scientific to expand its position in the high-growth ambulatory electrocardiography space, and further help to enter into the implantable cardiac monitor market to expand its cardiac diagnostics and services. Thus, such type of strategies adopted by key players is expected to enhance the market prospects for further growth and developments.
Market Coverage
o By Type
o By Device
o By Diagnosis
o By Treatment
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report:
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Myocardial Infarction Market Report Segment
By Type
By Device
By Diagnosis
By Treatment
o Analgesics
o Thrombolytic
o Anti-Platelet Agents
o Glycoprotein LIB/LIB Inhibitors
o Others (Beta-Adrenergic Blockers and Angiotensin-Receptor Blockers)
o Angioplasty
o CABG
o Heart Transplant
By End-Users
Global Myocardial Infarction Market Report by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/myocardial-infarction-market